New agreement was signed between AYOXXA, an international biotech company with headquarters in Cologne, and the Singapore Eye Research Institute (SERI), one of the leading international eye research institutes. AYOXXA and SERI will work together on validating the company’s multiplexing technology platform for protein biomarker detection, as part of an expanded collaboration for developing ophthalmic diagnostic tools.
SERI has had a long and broad history of working with large and mid-size pharmaceutical and ophthalmic companies, and the partnership with AYOXXA can potentially enable the co-development of a range of ophthalmic diagnostic tools, beginning with age-related macular degeneration (AMD).
Michael Rasche, Corporate Vice President Global Commercial Operations of AYOXXA Biosystems, said: “We are pleased to start this collaboration with such a prestigious research institute like SERI. By gaining access to very low-volume samples from the eye we can prove the benefits of our new protein multiplex technology beyond the research segment in clinical settings. We want to closely work with SERI in the ophthalmology space and potentially use our technology as new diagnostic application in the treatment of AMD.